19:25 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Hypertension Patient sample, cell culture, mouse and rat studies suggest inhibiting ENO1 could help treat pulmonary arterial hypertension (PAH) associated with other conditions. In pulmonary artery smooth muscle cell samples from patients with PAH...
16:36 , Sep 21, 2018 |  BC Week In Review  |  Company News

United gets rights to Samumed's IPF compound

Samumed LLC (San Diego, Calif.) granted United Therapeutics Corp. (NASDAQ:UTHR) exclusive, U.S. and Canadian rights to idiopathic pulmonary fibrosis candidate SM04646, a Wnt signaling pathway inhibitor. Samumed will receive $10 million up front, and is...
22:02 , Sep 17, 2018 |  BC Extra  |  Company News

United gets rights to Samumed's IPF compound

Samumed LLC (San Diego, Calif.) granted United Therapeutics Corp. (NASDAQ:UTHR) exclusive, U.S. and Canadian rights to idiopathic pulmonary fibrosis candidate SM04646, a Wnt signaling pathway inhibitor. Samumed will receive $10 million up front, and is...
17:36 , Sep 7, 2018 |  BC Week In Review  |  Company News

MannKind stock climbs after closing treprostinil deal with United Therapeutics

MannKind Corp. (NASDAQ:MNKD; Tel Aviv:MNKD) shot up $0.98 (89%) to $2.08. on Sept. 4 after signing a deal with United Therapeutics Corp. (NASDAQ:UTHR) for rights to Treprostinil Technosphere. MannKind will receive $45 million up front...
01:40 , Aug 18, 2018 |  BioCentury  |  Regulation

Pediatric push

FDA has endorsed extrapolation of therapeutic efficacy from adults to children for new drugs to treat partial onset seizures in a draft guidance and is now discussing in public meetings whether the approach can be...
03:14 , Aug 17, 2018 |  BC Week In Review  |  Clinical News

United Therapeutics' Orenitram delays disease progression in Phase III for PAH

United Therapeutics Corp. (NASDAQ:UTHR) said Orenitram treprostinil met the primary endpoint in the double-blind, international Phase III FREEDOM-EV trial in 690 pulmonary arterial hypertension (PAH) patients on background oral monotherapy. Thrice-daily oral Orenitram significantly delayed...
18:42 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Phase III of Bellerophon's INOpulse for PAH stopped for futility

Bellerophon Therapeutics Inc. (NASDAQ:BLPH) said a DMC recommended stopping for futility the Phase III INOvation-1 trial of INOpulse to treat pulmonary arterial hypertension (PAH). A prespecified interim analysis of the first 75 patients who completed...
18:13 , Jul 27, 2018 |  BC Week In Review  |  Financial News

Liquidia prices $50M IPO

Liquidia Technologies Inc. (NASDAQ:LQDA) raised $50 million on July 25 through the sale of 4.5 million shares at $11 in an IPO underwritten by Jefferies, Cowen, Needham and Wedbush PacGrow. Liquidia priced the offering at...
17:02 , Jul 27, 2018 |  BC Week In Review  |  Company News

Milligan, Martin leaving Gilead

Gilead Sciences Inc. (NASDAQ:GILD) said President and CEO John Milligan will step down at year end. The company's board is searching for a successor. Milligan has been at Gilead for 28 years. He became CEO...
15:27 , Jul 26, 2018 |  BC Extra  |  Financial News

Liquidia prices $50M IPO

Liquidia Technologies Inc. (NASDAQ:LQDA) added $0.10 to $11.10 on Thursday after raising $50 million through the sale of 4.5 million shares at $11 in an IPO underwritten by Jefferies, Cowen, Needham and Wedbush PacGrow. Liquidia...